首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells
【24h】

By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells

机译:通过抑制SRC,Verapamil和Dasatinib通过增加BIM的表达和MDR1和Survivin的表达增加,克服多药抗性,并且在人类多药中的骨髓瘤细胞中的表达

获取原文
获取原文并翻译 | 示例
           

摘要

The calcium channel blocker verapamil inhibits the transport function of multidrug resistance protein 1 (MDR1). Although verapamil acts to reverse MDR in cancer cells, the underlying mechanism remains unclear. In the present study, we investigated the mechanism of reversing MDR by verapamil in anti-cancer drug-resistant multiple myeloma (MM) cell lines. We found that verapamil suppresses MDR1 and survivin expressions and increases Bim expression via suppression of Src activation. Furthermore, dasatinib reversed the drug-resistance of the drug-resistant cell lines. These findings suggest that Src inhibitors are potentially useful as an anti-MDR agent for the treatment of malignant tumor cells.
机译:钙通道阻滞剂维拉帕米抑制多药抗性蛋白1(MDR1)的运输功能。 虽然维拉帕米采用癌细胞中的MDR,但下面的机制仍然不清楚。 在本研究中,我们调查了维拉帕米在抗癌毒性多发性骨髓瘤(MM)细胞系中逆转MDR的机制。 我们发现维拉帕米抑制了MDR1和Survivin表达,并通过抑制SRC活化来增加BIM表达。 此外,Dasatinib反转耐药细胞系的耐药性。 这些发现表明,SRC抑制剂可能用作治疗恶性肿瘤细胞的抗MDR剂。

著录项

  • 来源
  • 作者单位

    Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;

    Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;

    Department of Pathology Kinki University School of Medicine Osakasayama Osaka Japan;

    Department of Surgery Kinki University School of Medicine Osakasayama Osaka Japan;

    Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;

    Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;

    Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;

    Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;

    Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;

    Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;

    Department of Pharmacy Izumi Municipal Hospital Izumi Osaka Japan;

    Department of Pharmacy Japanese Red Cross Society Wakayama Medical Center Wakayama Japan;

    Department of Pathology Kinki University School of Medicine Osakasayama Osaka Japan;

    Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    Bim; Dasatinib; Drug resistance; MDR1; Multiple myeloma; Src; Survivin; Verapamil;

    机译:bim;达司替尼;耐药;mdr1;多发性骨髓瘤;src;survivin;verapamil;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号